Table 2.
Endometrial hyperplasia incidence and immunohistochemical expression of phosphorylated S6 ribosomal protein and serine phosphorylated IRS-1 in vehicle and WAY-129327-treated Eker (Tsc2+/−) rat endometrium. All rat endometrial sections expressed IRS-1 and/or IRS-2. *, statistical significance was evaluated between the vehicle and WAY-129327-treated groups by χ2 analysis.
| Treatment | # of hyperplastic foci/# uterine cross sections |
% hyperplastic foci (+) for phospho-(S235) S6 |
% hyperplastic foci (+) for phospho-(S636/639) IRS-1 |
|---|---|---|---|
| Vehicle 1 | 2/2 | 100% | 0% |
| Vehicle 2 | 1/1 | 100% | 0% |
| Vehicle 3 | 1/8 | 100% | 0% |
| Vehicle 4 | 7/10 | 100% | 0% |
| Vehicle 5 | 6/12 | 100% | 0% |
| Vehicle 6 | 5/6 | 100% | 0% |
| Vehicle 7 | 3/12 | 100% | 0% |
| Vehicle 8 | 8/9 | 100% | 0% |
| Vehicle 9 | 3/10 | 100% | 0% |
| Vehicle 10 | 8/9 | 100% | 0% |
| Vehicle 11 | 10/10 | 100% | 0% |
| Total | 54/89 (61%) | ||
| WAY-129327 | 1/8 | 0% | 0% |
| WAY-129327 | 1/11 | 0% | 0% |
| WAY-129327 | 1/10 | 0% | 0% |
| WAY-129327 | 0/15 | N/Aa | N/Aa |
| WAY-129327 | 0/11 | N/Aa | N/Aa |
| WAY-129327 | 0/11 | N/Aa | N/Aa |
| WAY-129327 | 0/13 | N/Aa | N/Aa |
| WAY-129327 | 3/11 | 0% | 30% |
| Total | 6/90 (7%) | ||
| p-value* | <0.001 | <0.001 | NS |
*
statistical significance was evaluated between the vehicle and WAY-129327-treated groups by χ2 analysis.
a
Not applicable due to lack of endometrial hyperplasia.